Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells

EGFR tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC) patients is inevitable. Identification of resistance mechanisms and corresponding targeting strategies can lead to more successful later-line treatment in many patients. Using spectrometry-based proteomics, we iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Terp, Mikkel G., Jacobsen, Kirstine, Molina, Miguel Angel, Karachaliou, Niki, Beck, Hans C., Bertran-Alamillo, Jordi, Giménez-Capitán, Ana, Cardona, Andrés F., Rosell, Rafael, Ditzel, Henrik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282882/
https://www.ncbi.nlm.nih.gov/pubmed/34267282
http://dx.doi.org/10.1038/s41698-021-00208-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282882/
https://www.ncbi.nlm.nih.gov/pubmed/34267282
http://dx.doi.org/10.1038/s41698-021-00208-w

Ejemplares similares